Author:
V.V. KOVALCHUK
St. Petersburg GBUZ City Hospital No. 38 named after N.A. Semashko, St. Petersburg
Author:
V.V. KOVALCHUK
St. Petersburg GBUZ City Hospital No. 38 named after N.A. Semashko, St. Petersburg
Place of publication:
JOURNAL OF NEUROLOGY AND PSYCHIATRY, 3, 2014
Abstract:
The aim of the study was to analyze the efficacy of Mexidol in the secondary prevention of ischemic stroke (IS). Material and Methods. The analysis included treatment outcomes in 3,400 patients who had suffered IS and were divided into 7 groups: patients with cryptogenic IS, hypertension, atrial fibrillation, metabolic syndrome, obstructive sleep apnea/hypnea syndrome, diabetes mellitus, and vasculitis. Treatment efficacy was assessed based on the absence of recurrent IS within 5 years of therapy. Results. Mexidol reduces the incidence of recurrent IS both in patients without comorbidities and in patients with hypertension, obstructive sleep apnea/hypnea syndrome, vasculitis, diabetes mellitus, atrial fibrillation, and metabolic syndrome. Conclusion. Further studies of the efficacy of Mexidol in the secondary prevention of IS appear promising. Key words: stroke, secondary prevention, mexidol.
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com